THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.2] ID: TIP-MED-000186

Vitamin D3 (Cholecalciferol — including 60,000 IU High-Strength Preparations)

Active Ingredient / Scientific Identity: Vitamin D3 • Class: Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol])

⚖️ Compare Profile
Generic / Entity NameVitamin D3 (Cholecalciferol — including 60,000 IU High-Strength Preparations) ([10.2])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassFat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Ren
Available Dosage FormsHigh-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solut
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Vitamin D3 (Cholecalciferol — including 60,000 IU High-Strength Preparations) (TIP-MED-000186, Reference Code [10.2]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol]). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.2], p. 127): Uprise-D3 60K (Alkem), Calcirol 60K (Cadila), Arachitol 60K / Nano (Abbott), D-Rise 60K (USV), Lumia 60K (Sun Pharma), Tayo 60K; Daily Maintenance Drops/Tablets: 400 IU, 1000 IU, 2000 IU — Strengths & Dosage Forms: High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.2], p. 127): Uprise-D3 60K (Alkem), Calcirol 60K (Cadila), Arachitol 60K / Nano (Abbott), D-Rise 60K (USV), Lumia 60K (Sun Pharma), Tayo 60K; Daily Maintenance Drops/Tablets: 400 IU, 1000 IU, 2000 IU — Strengths & Dosage Forms: High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)
Dosage Forms & Available Strengths:
High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol]) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol]) for Treatment and prevention of Vitamin D deficiency (<20 ng/mL) and insufficiency (20–30 ng/mL); nutritional osteomalacia and rickets; adjunct to calcium and bisphosphonates in osteoporosis; prevention of corticosteroid-induced and anticonvulsant-induced bone loss; reduction of proximal myopathy and falls in the elderly..

4. Therapeutic Indications & Evidence-Supported Uses

  • Treatment and prevention of Vitamin D deficiency (<20 ng/mL) and insufficiency (20–30 ng/mL)
  • nutritional osteomalacia and rickets
  • adjunct to calcium and bisphosphonates in osteoporosis
  • prevention of corticosteroid-induced and anticonvulsant-induced bone loss
  • reduction of proximal myopathy and falls in the elderly

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference (Endocrine Society / Indian Consensus): • Loading Phase (Deficiency Correction): 60,000 IU orally ONCE A WEEK (e.g., every Sunday) for 6 to 8 weeks! • Maintenance Phase: 60,000 IU orally ONCE A MONTH (or 1000–2000 IU daily). CRITICAL WARNING: 60,000 IU is a WEEKLY/MONTHLY strength—NEVER take 60,000 IU daily! Follow physician prescription.

Administration & Meal Timing: MUST be taken WITH a fat-containing meal or a glass of warm full-cream milk! (Vitamin D3 is highly lipophilic/fat-soluble; taking a 60,000 IU capsule or sachet with a meal containing healthy fats [milk, curd, ghee, nuts, dal] increases intestinal lymphatic absorption by 32% to 50% compared to taking it with plain water on an empty stomach!). | Once weekly (on a fixed day, e.g., Sunday) immediately after breakfast, lunch, or dinner (or with bedtime milk).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.
Elimination & Renal Adjustment:
Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.
Hepatic Impairment Considerations:
Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in hypercalcaemia, hypervitaminosis D, malabsorption syndromes (unless water-miscible nano-micellar oral shots are used), and hypercalciuria/active calcium nephrolithiasis. Caution in sarcoidosis and granulomatous diseases (tuberculosis/lymphoma—macrophages convert 25(OH)D to active 1,25(OH)2D in an unregulated manner, causing hypercalcaemia!).

Key Clinical Precautions: Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Zero adverse effects within physiological replacement doses.
  • Hypervitaminosis D and Severe Hypercalcaemia (Serum 25(OH)D >100–150 ng/mL, caused by accidental daily intake of 60,000 IU capsules or repeated unmonitored 6,00,000 IU IM injections!): presents with anorexia,intractable nausea, vomiting, constipation, polyuria, polydipsia, confusion/lethargy, nephrocalcinosis, renal calculi, and Acute Kidney Injury!
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Thiazide Diuretics (Chlorthalidone, Hydrochlorothiazide) reduce urinary calcium excretion—combining thiazides with high-dose Vitamin D + Calcium can precipitate hypercalcaemia! Digoxin: Hypercalcaemia from Vitamin D overdose triggers fatal digoxin cardiac arrhythmias! Phenytoin, Carbamazepine, Phenobarbitone, and Rifampicin induce CYP24A1 catabolism of Vitamin D (increasing requirements)
  • Orlistat, Cholestyramine, and Liquid Paraffin block fat-soluble Vitamin D absorption

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: See Section 10.12 for the complete Vitamin D3 60,000 IU clinical protocol. Always write the exact 8-week stop/transition date on the pouch so the patient does not keep taking 60,000 IU every week for a year!
  • Meal & Clock Timing Instruction: MUST be taken WITH a fat-containing meal or a glass of warm full-cream milk! (Vitamin D3 is highly lipophilic/fat-soluble; taking a 60,000 IU capsule or sachet with a meal containing healthy fats [milk, curd, ghee, nuts, dal] increases intestinal lymphatic absorption by 32% to 50% compared to taking it with plain water on an empty stomach!). (Once weekly (on a fixed day, e.g., Sunday) immediately after breakfast, lunch, or dinner (or with bedtime milk).)
  • Missed Dose Protocol: If the weekly Sunday dose is forgotten, take it with a meal/milk on Monday or Tuesday, then resume the normal Sunday schedule the following week.
  • Geriatric Dispensing Pearl: Correcting Vitamin D deficiency (<20 ng/mL) in elderly CGHS patients improves quadriceps muscle strength, reduces postural sway, reduces fall risk by ~20%, and prevents bisphosphonate-induced hypocalcaemia.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.2] (p. 127)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.